Drug Information Association
Drug Information Association is a nonprofit, worldwide association that aims to foster innovation, improve public health globally and provide a forum for knowledge exchange. It has more than 18,000 members in more than eighty countries drawn from the discovery, development and management disciplines of pharmaceuticals and medical devices.
The DIA was founded in 1964 in the state of Maryland, United States by a group of thirty pharmaceutical professionals, medical writers and academicians who saw the need to facilitate communications and foster cooperative efforts among professionals working in health care industries primarily engaged in drug development, medical communications and health information. The founding of DIA was closely tied to the passing of the Kefauver-Harris Amendment on the heels of the devastation of thalidomide, a sedative used to treat morning sickness in pregnant women that was causing birth defects in Europe, Canada and other countries. Thomas Teal, a long-time pharmaceutical executive and DIA’s founder, felt strongly that a vehicle that provided accurate up-to -date pharmaceutical information was needed more than ever, thus the founding of DIA and eventually the publication of pharmaceutical research in the association’s official journal, The Drug Information Journal. (Read more about this landmark ruling at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm322856.html).
Over the past 50 years, DIA has grown into an international, highly respected organization. The Association is fully independent; this ensures an unbiased environment for the Associations’ activities and goals. DIA provides educational and professional development opportunities for individuals working in the pharmaceutical and medical product development-related fields, as well as a global, unbiased forum for the exchange of information across multiple disciplines of programming and publications. These opportunities help facilitate the process of bringing life-saving medicines and health care technologies to the world.
To achieve these goals, DIA offers a large selection of meetings, webinars, e-learning and training programs throughout the world. The Association also provides three regular publications to its members including: The Global Forum, a news and information digital resource that keeps members advised of activities and events at the Association as well as current trends in the health care arena; Therapeutic Innovation & Regulatory Science, DIA’s official scholarly, peer-reviewed journal; and the CSO Directory, an annual, international digital reference guide compiling information from drug development and clinical trial companies.
The Association is governed by an international Board of Directors. A new president is elected each year by the members of DIA during the North America Annual Meeting. The Global Chief Executive is seated in the global center, located in Washington, DC and oversees the activities of the Association’s executive leadership, ensuring cohesive, global efforts to support the Association’s strategic plan.
- Professional development through conferences and meetings.
- Training courses including in-company training, certificate programs and online training.
- Continuing education for healthcare professionals.
- Publications including drug information journals and magazines and a newsletter.
- Career guidance and job opportunities.
- Creation of reference models including that for Trial master files